,56 In this study, we used scFv-SNAP-tag, targeting ovarian cancer cells expressing EGFR, Her2, FOLR1, TROP2, and TF antigen to generate 1:1 antibody IR700 ratio, which is important to get robust pharmacokinetic, efficacy, and safety profiles.40 This evidence concerns the gene FOLR1 and ovarian carcinoma.